Spotlight on Gastroenterology

Credits: 0.75 CME / MOC
Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients
Parambir Dulai, MD
The Postgraduate Institute for Medicine

Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the needs of gastroenterologists, GI surgeons, and other GI-focused clinicians who manage patients with Crohn’s disease (CD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the benefits of a treat-to-target strategy in Crohn’s disease (CD) aimed at deep remission
  • Use clinical decision support tools to risk stratify patients for individualized CD care
  • Employ shared decision making for patient-centered and empowered CD care

Activity Description

During this activity, 3 inflammatory bowel disease (IBD) experts discuss the latest real-world insights on treat-to-target strategies in CD, tools to help risk stratify patients with CD, and a personalized approach to care.

Statement of Educational Need

The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits, including reducing underlying inflammation and improving long-term outcomes. Because the disease course in CD can vary widely, there has been significant effort directed toward developing risk stratification tools and evidence-based guideline management. Despite the evidence supporting the usefulness of patient-specific risk stratification, many patients with CD suffer disease progression and complications. When patients are involved in their own care through shared decision making, they are more educated about treatment options, confident in their treatment plan, and have a better quality of life.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
La Jolla, CA


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH


David T. Rubin, MD, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Parambir Dulai, MD, has affiliations with Janssen, Pfizer, Takeda (Consultant); Janssen (Contracted Research).

Corey A. Siegel, MD, MS, has affiliations with CDPATH Risk Prediction Tool (Receipt of Intellectual Property Rights/Patent Holder); AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Prometheus Laboratories, Takeda (Consultant); Pfizer (Contracted Research); ColonaryConcepts, MiTest Health (Stocks, stock options or other ownership interest excluding diversified mutual funds); AbbVie, Janssen, Pfizer, Takeda (Speaker for CME Programs).

David T. Rubin, MD, FACG, AGAF, FACP, has affiliations with AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), InDex Pharmaceuticals, Iterative Scopies, Janssen, Lilly, Materia Prima, Narrow River Management, Pfizer, Prometheus Laboratories, Reistone, Takeda, Techlab, Inc (Consultant); Takeda (Grant Support); American College of Gastroenterology (Board of Trustees); Cornerstones Health, Inc. (non-profit) (Co-Founder, CFO); GoDuRn, LLC (Co-Founder).

Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from July 7, 2021 through July 6, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For more information about the accreditation of this program, please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the needs of gastroenterologists, GI surgeons, and other GI-focused clinicians who manage patients with Crohn’s disease (CD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the benefits of a treat-to-target strategy in Crohn’s disease (CD) aimed at deep remission
  • Use clinical decision support tools to risk stratify patients for individualized CD care
  • Employ shared decision making for patient-centered and empowered CD care

Activity Description

During this activity, 3 inflammatory bowel disease (IBD) experts discuss the latest real-world insights on treat-to-target strategies in CD, tools to help risk stratify patients with CD, and a personalized approach to care.

Statement of Educational Need

The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits, including reducing underlying inflammation and improving long-term outcomes. Because the disease course in CD can vary widely, there has been significant effort directed toward developing risk stratification tools and evidence-based guideline management. Despite the evidence supporting the usefulness of patient-specific risk stratification, many patients with CD suffer disease progression and complications. When patients are involved in their own care through shared decision making, they are more educated about treatment options, confident in their treatment plan, and have a better quality of life.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
La Jolla, CA


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH


David T. Rubin, MD, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Parambir Dulai, MD, has affiliations with Janssen, Pfizer, Takeda (Consultant); Janssen (Contracted Research).

Corey A. Siegel, MD, MS, has affiliations with CDPATH Risk Prediction Tool (Receipt of Intellectual Property Rights/Patent Holder); AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Prometheus Laboratories, Takeda (Consultant); Pfizer (Contracted Research); ColonaryConcepts, MiTest Health (Stocks, stock options or other ownership interest excluding diversified mutual funds); AbbVie, Janssen, Pfizer, Takeda (Speaker for CME Programs).

David T. Rubin, MD, FACG, AGAF, FACP, has affiliations with AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), InDex Pharmaceuticals, Iterative Scopies, Janssen, Lilly, Materia Prima, Narrow River Management, Pfizer, Prometheus Laboratories, Reistone, Takeda, Techlab, Inc (Consultant); Takeda (Grant Support); American College of Gastroenterology (Board of Trustees); Cornerstones Health, Inc. (non-profit) (Co-Founder, CFO); GoDuRn, LLC (Co-Founder).

Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from July 7, 2021 through July 6, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For more information about the accreditation of this program, please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

Gastroenterology Presentations

1.00 CME
Integrity Continuing Education, Inc.
Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 29, 2022
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants

Learning Objectives

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE

Activity Description

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps and patient case scenarios will illustrate the utility of these agents in clinical practice.

Statement of Educational Need

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life, and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

Program Chair

Ikuo Hirano, MD
Director, Esophageal Center at
Northwestern University, Feinberg School of Medicine
Professor of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Faculty

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia


Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ikuo Hirano, MD (Program Chair)
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire/Takeda

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologies
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC, reported that they or their spouse/life partner, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021, through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 29, 2022
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants

Learning Objectives

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE

Activity Description

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps and patient case scenarios will illustrate the utility of these agents in clinical practice.

Statement of Educational Need

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life, and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

Program Chair

Ikuo Hirano, MD
Director, Esophageal Center at
Northwestern University, Feinberg School of Medicine
Professor of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Faculty

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia


Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ikuo Hirano, MD (Program Chair)
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire/Takeda

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologies
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC, reported that they or their spouse/life partner, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021, through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

0.50 CME / CNE
Postgraduate Institute for Medicine
Activity 2: This or That? An Analysis of Real-World Studies Investigating Biologics in Crohn’s Disease (CD)

Activity 2: This or That? An Analysis of Real-World Studies Investigating Biologics in Crohn’s Disease (CD)

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
30 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Evaluate outcomes from real-world comparative studies investigating the efficacy and safety of biologic therapies within the treatment of CD
  • Inform therapeutic decisions regarding the use of non–tumor necrosis factor (TNF) inhibitor therapies for CD with the latest evidence, expert recommendations, and patient/disease profiles

Program Description

During this guided journal club tour, Dr. Sands will review and discuss the real-world effectiveness and safety of vedolizumab and ustekinumab according to outcomes from 2 individual cohort studies with the goal of indirectly comparing results to determine the best use of these therapies within the management of patients with moderate to severe Crohn’s disease. Currently, head-to-head studies are lacking among advanced, non-TNF inhibitor therapies for Crohn’s disease. Furthermore, although real-world data are also scarce, these types of studies can be used to bridge knowledge gaps that may not be addressed by controlled clinical trials.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
30 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Evaluate outcomes from real-world comparative studies investigating the efficacy and safety of biologic therapies within the treatment of CD
  • Inform therapeutic decisions regarding the use of non–tumor necrosis factor (TNF) inhibitor therapies for CD with the latest evidence, expert recommendations, and patient/disease profiles

Program Description

During this guided journal club tour, Dr. Sands will review and discuss the real-world effectiveness and safety of vedolizumab and ustekinumab according to outcomes from 2 individual cohort studies with the goal of indirectly comparing results to determine the best use of these therapies within the management of patients with moderate to severe Crohn’s disease. Currently, head-to-head studies are lacking among advanced, non-TNF inhibitor therapies for Crohn’s disease. Furthermore, although real-world data are also scarce, these types of studies can be used to bridge knowledge gaps that may not be addressed by controlled clinical trials.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 CME / CNE
Postgraduate Institute for Medicine
Activity 1: Beyond TNF Inhibitors in Ulcerative Colitis (UC): An Expert Tour of Data That Will Help You Navigate the Guidelines

Activity 1: Beyond TNF Inhibitors in Ulcerative Colitis (UC): An Expert Tour of Data That Will Help You Navigate the Guidelines

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
60 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Comprehensively evaluate and risk stratify patients with UC to identify individuals who should be managed with advanced therapies
  • Analyze clinical evidence of current biologic and small molecule inhibitor therapies for UC, including head-to-head trials and comparative meta-analyses
  • Utilize guideline recommendations and available clinical evidence to inform first-line treatment selection of advanced therapies for the induction of remission in UC

Program Description

During this guided tour of the American Gastroenterological Association (AGA) Clinical Practice Guidelines, Dr. Sands will review and discuss recommendations that center on the outpatient management of moderate to severe ulcerative colitis. Currently, there are an increasing number of effective non–tumor necrosis factor (TNF) inhibitor therapeutic options available for the treatment of UC. However, utilization of these advanced therapies may present a challenge to current clinical practice as guidance on their positioning within the treatment algorithm is limited and often based on indirect evidence. Therefore, Dr. Sands will walk learners through the publication while providing his interpretation and evaluation of recommendations and highlight key findings to consider when determining the best treatment strategy for each patient.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
60 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Comprehensively evaluate and risk stratify patients with UC to identify individuals who should be managed with advanced therapies
  • Analyze clinical evidence of current biologic and small molecule inhibitor therapies for UC, including head-to-head trials and comparative meta-analyses
  • Utilize guideline recommendations and available clinical evidence to inform first-line treatment selection of advanced therapies for the induction of remission in UC

Program Description

During this guided tour of the American Gastroenterological Association (AGA) Clinical Practice Guidelines, Dr. Sands will review and discuss recommendations that center on the outpatient management of moderate to severe ulcerative colitis. Currently, there are an increasing number of effective non–tumor necrosis factor (TNF) inhibitor therapeutic options available for the treatment of UC. However, utilization of these advanced therapies may present a challenge to current clinical practice as guidance on their positioning within the treatment algorithm is limited and often based on indirect evidence. Therefore, Dr. Sands will walk learners through the publication while providing his interpretation and evaluation of recommendations and highlight key findings to consider when determining the best treatment strategy for each patient.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / MOC
RMEI Medical Education, LLC
Assessing the Potential Patient Care Implications of New Data in Eosinophilic Esophagitis

Assessing the Potential Patient Care Implications of New Data in Eosinophilic Esophagitis

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Points
Released: July 14, 2021
Expires: July 13, 2022
30 minutes to complete

Provided By

This activity is provided by AGA Institute and has been developed through a collaboration between AGA Institute and RMEI Medical Education, LLC.

Target Audience

Gastroenterologists, pediatric gastroenterologists, allergy/immunologists, pediatric allergy/immunologists, and other healthcare professionals involved in the treatment of patients with eosinophilic esophagitis (EoE).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess recently presented data on current approaches for the management of eosinophilic esophagitis (EoE)
  • Summarize new findings related to immune pathophysiologic pathways and therapeutic targets for EoE
  • Analyze late-breaking data related to the efficacy, safety, and tolerability of new and emerging therapies for treatment of EoE

Activity Description

In this activity, 2 experts in the diagnosis and management of eosinophilic esophagitis (EoE) analyze data on the treatment of this disease that was presented at the 2021 Digestive Disease Week virtual meetings. Topics for discussion include updates on current management approaches for EoE, new research highlighting the pathophysiological underpinnings of EoE, and late-breaking data on emerging treatment approaches for individuals with EoE.

Chair

Evan S. Dellon, MD, MPH
Professor, Medicine
Adjunct Professor, Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Faculty

Amanda B. Muir, MD, MTR
Attending Physician
Children’s Hospital of Philadelphia, Research Institute
Philadelphia, PA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Evan S. Dellon, MD, MPH, has affiliations with Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consulting Fees).

Amanda B. Muir, MD, MTR, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Disclosure
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Points
Released: July 14, 2021
Expires: July 13, 2022
30 minutes to complete

Provided By

This activity is provided by AGA Institute and has been developed through a collaboration between AGA Institute and RMEI Medical Education, LLC.

Target Audience

Gastroenterologists, pediatric gastroenterologists, allergy/immunologists, pediatric allergy/immunologists, and other healthcare professionals involved in the treatment of patients with eosinophilic esophagitis (EoE).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess recently presented data on current approaches for the management of eosinophilic esophagitis (EoE)
  • Summarize new findings related to immune pathophysiologic pathways and therapeutic targets for EoE
  • Analyze late-breaking data related to the efficacy, safety, and tolerability of new and emerging therapies for treatment of EoE

Activity Description

In this activity, 2 experts in the diagnosis and management of eosinophilic esophagitis (EoE) analyze data on the treatment of this disease that was presented at the 2021 Digestive Disease Week virtual meetings. Topics for discussion include updates on current management approaches for EoE, new research highlighting the pathophysiological underpinnings of EoE, and late-breaking data on emerging treatment approaches for individuals with EoE.

Chair

Evan S. Dellon, MD, MPH
Professor, Medicine
Adjunct Professor, Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Faculty

Amanda B. Muir, MD, MTR
Attending Physician
Children’s Hospital of Philadelphia, Research Institute
Philadelphia, PA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Evan S. Dellon, MD, MPH, has affiliations with Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consulting Fees).

Amanda B. Muir, MD, MTR, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Disclosure
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

0.75 CME / MOC
The Postgraduate Institute for Medicine
Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients

Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the needs of gastroenterologists, GI surgeons, and other GI-focused clinicians who manage patients with Crohn’s disease (CD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the benefits of a treat-to-target strategy in Crohn’s disease (CD) aimed at deep remission
  • Use clinical decision support tools to risk stratify patients for individualized CD care
  • Employ shared decision making for patient-centered and empowered CD care

Activity Description

During this activity, 3 inflammatory bowel disease (IBD) experts discuss the latest real-world insights on treat-to-target strategies in CD, tools to help risk stratify patients with CD, and a personalized approach to care.

Statement of Educational Need

The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits, including reducing underlying inflammation and improving long-term outcomes. Because the disease course in CD can vary widely, there has been significant effort directed toward developing risk stratification tools and evidence-based guideline management. Despite the evidence supporting the usefulness of patient-specific risk stratification, many patients with CD suffer disease progression and complications. When patients are involved in their own care through shared decision making, they are more educated about treatment options, confident in their treatment plan, and have a better quality of life.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
La Jolla, CA


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH


David T. Rubin, MD, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Parambir Dulai, MD, has affiliations with Janssen, Pfizer, Takeda (Consultant); Janssen (Contracted Research).

Corey A. Siegel, MD, MS, has affiliations with CDPATH Risk Prediction Tool (Receipt of Intellectual Property Rights/Patent Holder); AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Prometheus Laboratories, Takeda (Consultant); Pfizer (Contracted Research); ColonaryConcepts, MiTest Health (Stocks, stock options or other ownership interest excluding diversified mutual funds); AbbVie, Janssen, Pfizer, Takeda (Speaker for CME Programs).

David T. Rubin, MD, FACG, AGAF, FACP, has affiliations with AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), InDex Pharmaceuticals, Iterative Scopies, Janssen, Lilly, Materia Prima, Narrow River Management, Pfizer, Prometheus Laboratories, Reistone, Takeda, Techlab, Inc (Consultant); Takeda (Grant Support); American College of Gastroenterology (Board of Trustees); Cornerstones Health, Inc. (non-profit) (Co-Founder, CFO); GoDuRn, LLC (Co-Founder).

Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from July 7, 2021 through July 6, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For more information about the accreditation of this program, please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the needs of gastroenterologists, GI surgeons, and other GI-focused clinicians who manage patients with Crohn’s disease (CD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the benefits of a treat-to-target strategy in Crohn’s disease (CD) aimed at deep remission
  • Use clinical decision support tools to risk stratify patients for individualized CD care
  • Employ shared decision making for patient-centered and empowered CD care

Activity Description

During this activity, 3 inflammatory bowel disease (IBD) experts discuss the latest real-world insights on treat-to-target strategies in CD, tools to help risk stratify patients with CD, and a personalized approach to care.

Statement of Educational Need

The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits, including reducing underlying inflammation and improving long-term outcomes. Because the disease course in CD can vary widely, there has been significant effort directed toward developing risk stratification tools and evidence-based guideline management. Despite the evidence supporting the usefulness of patient-specific risk stratification, many patients with CD suffer disease progression and complications. When patients are involved in their own care through shared decision making, they are more educated about treatment options, confident in their treatment plan, and have a better quality of life.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
La Jolla, CA


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH


David T. Rubin, MD, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Parambir Dulai, MD, has affiliations with Janssen, Pfizer, Takeda (Consultant); Janssen (Contracted Research).

Corey A. Siegel, MD, MS, has affiliations with CDPATH Risk Prediction Tool (Receipt of Intellectual Property Rights/Patent Holder); AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Prometheus Laboratories, Takeda (Consultant); Pfizer (Contracted Research); ColonaryConcepts, MiTest Health (Stocks, stock options or other ownership interest excluding diversified mutual funds); AbbVie, Janssen, Pfizer, Takeda (Speaker for CME Programs).

David T. Rubin, MD, FACG, AGAF, FACP, has affiliations with AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), InDex Pharmaceuticals, Iterative Scopies, Janssen, Lilly, Materia Prima, Narrow River Management, Pfizer, Prometheus Laboratories, Reistone, Takeda, Techlab, Inc (Consultant); Takeda (Grant Support); American College of Gastroenterology (Board of Trustees); Cornerstones Health, Inc. (non-profit) (Co-Founder, CFO); GoDuRn, LLC (Co-Founder).

Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from July 7, 2021 through July 6, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For more information about the accreditation of this program, please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

1.00 CME / MOC / CC
Vindico Medical Education
Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Start

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

2.00 CME
The Academy for Continued Healthcare Learning
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Start

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC

Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO

Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC

Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC

Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO

Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

0.50 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Taking Stock of Current Options and Emerging Approaches for the Management of EoE

Taking Stock of Current Options and Emerging Approaches for the Management of EoE

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC Point(s)
Released: May 31, 2021
Expires: May 30, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This curriculum is designed for gastroenterologists, allergists and immunologists, pediatric gastroenterologists, pediatric allergists and immunologists, and NPs/PAs who diagnose and manage patients with eosinophilic esophagitis (EoE).

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Recognize the value and limitations of current eosinophilic esophagitis (EoE) management guidelines for children and adults
  • Assess pathophysiologic pathways and evaluate emerging targeted therapies for EoE

Activity Description

This 30-minute infographic-based educational activity reviews current therapies for eosinophilic esophagitis (EoE), as well as emerging conventional and biologic approaches for its treatment. This activity is also augmented by patient and clinician videos discussing available and investigational therapies.

Statement of Educational Need

Although improved awareness of EoE has helped identify many patients with EoE, available therapies do not fully address patient symptoms or provide endoscopic and histologic resolution in many cases. However, several pathophysiologic pathways have now been described for EoE, and targeted therapies are under study that may provide relief for more patients. As such, clinicians who manage patients with this disorder need to stay current with potential treatment advances for EoE.

Chair

Evan S. Dellon, MD, MPH
Professor of Medicine, Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

FACULTY DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consultant); Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, GSK, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda (Contracted Research - paid to institution); Allakos, Banner, Holoclara (Other: Educational grants - paid to institution).

STAFF AND REVIEWERS DISCLOSURES
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

During the period May 31, 2021 through May 30, 2022, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the evaluation form

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
ABIM MOC Point(s)
Released: May 31, 2021
Expires: May 30, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This curriculum is designed for gastroenterologists, allergists and immunologists, pediatric gastroenterologists, pediatric allergists and immunologists, and NPs/PAs who diagnose and manage patients with eosinophilic esophagitis (EoE).

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Recognize the value and limitations of current eosinophilic esophagitis (EoE) management guidelines for children and adults
  • Assess pathophysiologic pathways and evaluate emerging targeted therapies for EoE

Activity Description

This 30-minute infographic-based educational activity reviews current therapies for eosinophilic esophagitis (EoE), as well as emerging conventional and biologic approaches for its treatment. This activity is also augmented by patient and clinician videos discussing available and investigational therapies.

Statement of Educational Need

Although improved awareness of EoE has helped identify many patients with EoE, available therapies do not fully address patient symptoms or provide endoscopic and histologic resolution in many cases. However, several pathophysiologic pathways have now been described for EoE, and targeted therapies are under study that may provide relief for more patients. As such, clinicians who manage patients with this disorder need to stay current with potential treatment advances for EoE.

Chair

Evan S. Dellon, MD, MPH
Professor of Medicine, Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

FACULTY DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consultant); Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, GSK, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda (Contracted Research - paid to institution); Allakos, Banner, Holoclara (Other: Educational grants - paid to institution).

STAFF AND REVIEWERS DISCLOSURES
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

During the period May 31, 2021 through May 30, 2022, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the evaluation form

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

0.25 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Getting the Diagnosis Right Early: Clinical Pearls for Identifying EOE in Children and Adults

Getting the Diagnosis Right Early: Clinical Pearls for Identifying EOE in Children and Adults

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: April 30, 2021
Expires: April 29, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This curriculum is designed for gastroenterologists, allergists and immunologists, pediatric gastroenterologists, pediatric allergists and immunologists, and NPs/PAs who diagnose and manage patients with eosinophilic esophagitis.

Learning Objective

Upon completion of the educational activity, participants should be able to:

  • Use evidence-based diagnostic approaches to detect eosinophilic esophagitis (EoE) early in children and adults

Activity Description

This 15-minute infographic-based educational activity will be augmented by patient and clinician videos, in addition to an interactive approach to cover diagnostic approaches to detect EoE early.

Statement of Educational Need

The significant burden of disease and increasing incidence and prevalence of eosinophilic esophagitis (EoE) in the United States require that several knowledge and practice gaps among clinicians involved in the care of affected patients be addressed; diagnostic delays continue to present a challenge to the timely management of EoE.

Agenda

  1. Incidence, prevalence, and underlying pathophysiology of EoE
  2. Symptomatology and natural history of EoE
  3. Diagnostic strategies for patients with a high index of suspicion for EoE
  4. Challenges associated with diagnosis and consequences of diagnostic delay

Chair

Evan S. Dellon, MD, MPH
Professor of Medicine, Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure Declaration

FACULTY DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consultant); Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda (Contracted Research - paid to institution); Allakos, Banner, Holoclara (Other: Educational grants - paid to institution)

STAFF AND REVIEWERS DISCLOSURES
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.  AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

During the period April 30, 2021 through April 29, 2022, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the evaluation form

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
ABIM MOC Point(s)
Released: April 30, 2021
Expires: April 29, 2022
15 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This curriculum is designed for gastroenterologists, allergists and immunologists, pediatric gastroenterologists, pediatric allergists and immunologists, and NPs/PAs who diagnose and manage patients with eosinophilic esophagitis.

Learning Objective

Upon completion of the educational activity, participants should be able to:

  • Use evidence-based diagnostic approaches to detect eosinophilic esophagitis (EoE) early in children and adults

Activity Description

This 15-minute infographic-based educational activity will be augmented by patient and clinician videos, in addition to an interactive approach to cover diagnostic approaches to detect EoE early.

Statement of Educational Need

The significant burden of disease and increasing incidence and prevalence of eosinophilic esophagitis (EoE) in the United States require that several knowledge and practice gaps among clinicians involved in the care of affected patients be addressed; diagnostic delays continue to present a challenge to the timely management of EoE.

Agenda

  1. Incidence, prevalence, and underlying pathophysiology of EoE
  2. Symptomatology and natural history of EoE
  3. Diagnostic strategies for patients with a high index of suspicion for EoE
  4. Challenges associated with diagnosis and consequences of diagnostic delay

Chair

Evan S. Dellon, MD, MPH
Professor of Medicine, Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure Declaration

FACULTY DISCLOSURES
Evan S. Dellon, MD, MPH, has disclosed the following relevant financial relationships: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consultant); Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda (Contracted Research - paid to institution); Allakos, Banner, Holoclara (Other: Educational grants - paid to institution)

STAFF AND REVIEWERS DISCLOSURES
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.  AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

Statements of credit will be awarded based on the participant reviewing each presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

During the period April 30, 2021 through April 29, 2022, participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the evaluation form

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

0.75 CME
Vindico Medical Education
Harnessing Immunological Pathways to Improve the Treatment of Moderate to Severe Crohn's Disease

Harnessing Immunological Pathways to Improve the Treatment of Moderate to Severe Crohn's Disease

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with moderate to severe Crohn’s disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.
  • Assess new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe Crohn’s disease.

Activity Description

Crohn’s disease (CD) is a chronic, progressive, idiopathic inflammatory disorder that can affect any component of the gastrointestinal tract. Approximately 780,000 individuals in the United States have CD, with the incidence and prevalence increasing worldwide. The ongoing clinical evaluation of emerging therapies with unique mechanisms of action holds promise for a more optimal disease response. Over the past 20 years, biologic agents have redefined the management of moderate to severe CD. Agents that impact not only clinical response and remission but also mucosal healing are now of paramount interest. Available biologic therapies for CD include anti–tumor necrosis factor-α agents, an integrin inhibitor, and interleukin 12/23 inhibitors—all of which are administered either intravenously or subcutaneously. Several oral small-molecule therapies are also under investigation for the treatment of moderate to severe CD, including Janus kinase protein inhibitors. Oral agents that modulate sphingosine 1-phosphate, which guides lymphocyte circulation through secondary lymphoid organs such as the spleen and lymph nodes, are being studied as well. In this CME activity, experts summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for treating moderate to severe CD. The most recent clinical findings on the safety and efficacy of therapies targeting immunological pathways are also evaluated.

Agenda

Targeting Immunological Pathways in CD
Bruce E. Sands, MD, MS

How Emerging Agents are Performing in Safety and Efficacy in Moderate to Severe CD
Jessica R. Allegretti, MD, MPH; William J. Sandborn, MD

Activity Chair

William J. Sandborn, MD
Distinguished Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
UC San Diego Health System
La Jolla, CA

Disclosures:
Consulting Fee: AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead, Gossamer Bio, Incyte, Janssen, Kyowa Kirin, Landos, Lilly, Oppilan, Otsuka, Pfizer, Progenity, Prometheus, Reistone, Seres, Shire, Sienna Biopharmaceuticals, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance, TiGenix, Tillotts, UCB, Ventyx, Vimalan Biosciences, Vivelix
Contracted Research: AbbVie, Amgen, Atlantic Healthcare, Celgene/Receptos, Genentech, Gilead, Janssen, Lilly, Pfizer, Prometheus, Takeda
Ownership Interest: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan, Progenity, Prometheus, Ritter, Shoreline, Ventyx, Vimalan Biosciences

Faculty

Jessica R. Allegretti, MD, MPH
Associate Director, Crohn’s and Colitis Center
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:
Consulting Fee: Artugen, Bacainn, Finch Therapeutics, Iterative Scopes, Janssen, Morphic Therapeutic, Pandion, Pfizer, Salix, Servatus, Takeda
Contracted Research: Merck


Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY

Disclosures:
Consulting Fee: Abivax, Arena Pharmaceuticals, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, Celltrion, Genentech, Gilead, GlaxoSmithKline, Index Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kallyope, Pfizer, Prometheus, Protagonist Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, Viela Bio

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at: CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with moderate to severe Crohn’s disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.
  • Assess new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe Crohn’s disease.

Activity Description

Crohn’s disease (CD) is a chronic, progressive, idiopathic inflammatory disorder that can affect any component of the gastrointestinal tract. Approximately 780,000 individuals in the United States have CD, with the incidence and prevalence increasing worldwide. The ongoing clinical evaluation of emerging therapies with unique mechanisms of action holds promise for a more optimal disease response. Over the past 20 years, biologic agents have redefined the management of moderate to severe CD. Agents that impact not only clinical response and remission but also mucosal healing are now of paramount interest. Available biologic therapies for CD include anti–tumor necrosis factor-α agents, an integrin inhibitor, and interleukin 12/23 inhibitors—all of which are administered either intravenously or subcutaneously. Several oral small-molecule therapies are also under investigation for the treatment of moderate to severe CD, including Janus kinase protein inhibitors. Oral agents that modulate sphingosine 1-phosphate, which guides lymphocyte circulation through secondary lymphoid organs such as the spleen and lymph nodes, are being studied as well. In this CME activity, experts summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for treating moderate to severe CD. The most recent clinical findings on the safety and efficacy of therapies targeting immunological pathways are also evaluated.

Agenda

Targeting Immunological Pathways in CD
Bruce E. Sands, MD, MS

How Emerging Agents are Performing in Safety and Efficacy in Moderate to Severe CD
Jessica R. Allegretti, MD, MPH; William J. Sandborn, MD

Activity Chair

William J. Sandborn, MD
Distinguished Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
UC San Diego Health System
La Jolla, CA

Disclosures:
Consulting Fee: AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead, Gossamer Bio, Incyte, Janssen, Kyowa Kirin, Landos, Lilly, Oppilan, Otsuka, Pfizer, Progenity, Prometheus, Reistone, Seres, Shire, Sienna Biopharmaceuticals, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance, TiGenix, Tillotts, UCB, Ventyx, Vimalan Biosciences, Vivelix
Contracted Research: AbbVie, Amgen, Atlantic Healthcare, Celgene/Receptos, Genentech, Gilead, Janssen, Lilly, Pfizer, Prometheus, Takeda
Ownership Interest: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan, Progenity, Prometheus, Ritter, Shoreline, Ventyx, Vimalan Biosciences

Faculty

Jessica R. Allegretti, MD, MPH
Associate Director, Crohn’s and Colitis Center
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:
Consulting Fee: Artugen, Bacainn, Finch Therapeutics, Iterative Scopes, Janssen, Morphic Therapeutic, Pandion, Pfizer, Salix, Servatus, Takeda
Contracted Research: Merck


Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY

Disclosures:
Consulting Fee: Abivax, Arena Pharmaceuticals, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, Celltrion, Genentech, Gilead, GlaxoSmithKline, Index Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kallyope, Pfizer, Prometheus, Protagonist Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, Viela Bio

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at: CME@VindicoCME.com

Pages